Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1123-4683 | Other Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors and undiagnosed diabetes in a screening study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Total study population |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | The screening test includes a combination of a risk assessment questionnaire and biochemical tests. |
|
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c (Glycosylated Haemoglobin) level | measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of subjects with diabetes (type 1 and 2) | measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) | |
| The presence of retinopathy | measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The Changing Diabetes® World Tour is designed as a mobile screening clinic staying for a minimum of 14 days in each location such as malls, public squares, etc. Subjects included in the study are either actively seeking to be screened, or are invited by subjects in their network already included in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Paço de Arcos | 2780-730 | Portugal | |||
| Novo Nordisk Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23331167 | Result | Handlos LN, Witte DR, Almdal TP, Nielsen LB, Badawi SE, Sheikh AR, Belhadj M, Nadir D, Zinai S, Vistisen D. Risk scores for diabetes and impaired glycaemia in the Middle East and North Africa. Diabet Med. 2013 Apr;30(4):443-51. doi: 10.1111/dme.12118. |
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003922 | Diabetes Mellitus, Type 1 |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Riyadh |
| 3542 |
| Saudi Arabia |
| Novo Nordisk Investigational Site | Dubai | United Arab Emirates |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |